ESMO Breast 2023 | MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Patrick Neven, MD, PhD, UZ Leuven, Leuven, Belgium, discusses an update in the MONALEESA-2 trial (NCT01958021). This study analyzed a subgroup of patients with HR+/HER2- advanced breast cancer who had de novo metastatic disease or late recurrence. The patients were treated with either letrozole + ribociclib or placebo + letrozole, and the study measured their overall survival (OS), progression-free survival (PFS), time to chemotherapy (TTC), and chemotherapy-free survival (CFS). The analysis found that the median OS was 69.2 months with ribociclib and 54.3 months with placebo, and ribociclib treatment also showed improvement in TTC and CFS. No new safety signals were observed. These results suggest that ribociclib may provide a significant survival benefit as a first-line treatment for HR+/HER2- advanced breast cancer patients. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.